Amarna Therapeutics announces appointment of Aurelia Caparrós as new Chief Business Officer
2024年4月19日 - 5:07PM
Leiden, The Netherlands, 19 April 2024
– Amarna Therapeutics, a privately-held biotechnology
company developing transformative gene therapies in a range of rare
and prevalent diseases, including Type 1 Diabetes Mellitus,
today announces the appointment of Aurelia Caparrós as the
Company’s new Chief Business Officer (CBO), effective 1st of April
2024.
Aurelia brings more than 25 years of healthcare
industry experience with expertise in business development,
strategy and global marketing including P&L responsibilities
spanning diverse geographies. She held global leadership roles for
amongst others Novartis, led multiple enterprise transformation
programs and implemented strategic growth initiatives to achieve
business goals while fostering the culture of inclusion and
enterprise mindset. As the new CBO, she will be responsible for
driving Amarna's future growth and expansion, both in the
Netherlands and Spain.
Her key responsibilities will include
identifying assets, companies, and areas of interest, designing
tailored partnering structures, and securing attractive deals
through the entire deal-making process. Aurelia will also play a
crucial role in promoting Amarna as the partner of choice at
business partnering meetings and scientific conferences, as well as
supporting the company's investor relations and fundraising
activities.
"We are thrilled to welcome Aurelia Caparrós as
our new Chief Business Officer," said Henk Streefkerk, CEO and
Medical Director of Amarna Therapeutics BV. "Her exceptional
leadership and deep industry expertise will be invaluable as we
continue to expand our business and bring our transformative gene
therapies to patients in need."
=== E N D S ===
About AmarnaAmarna Therapeutics has
developed a groundbreaking non-immunogenic viral platform to
deliver any transgene of choice into humans. It is advancing a
pipeline of transformative gene therapies for a range of rare and
prevalent diseases, including monogenetic indications, autoimmune
diseases and chronic inflammation. The lead program Nimvec™ AM510
is being developed for the treatment of patients with Type 1
Diabetes Mellitus. Follow up programs include Multiple Sclerosis,
Age-related Macular Degeneration, and Hemophilia.
About Type 1 Diabetes MellitusType 1
Diabetes is a debilitating disease occurring in millions of
patients globally, with rising incidences each year, where despite
advancements in therapy the life expectancy remains lower than the
general population. Diabetes is an autoimmune disease where
self-reactive T lymphocytes selectively attack and destroy
insulin-producing β cells lodged within the pancreas, leaving the
patient unable to maintain glucose homeostasis. Proinsulin (PI) is
the primary self-antigen involved in the autoimmune β cell
destruction. To date, Type 1 Diabetes cannot be cured, and the
glucose homeostasis can be more or less maintained in patients by
daily insulin injections. Although Diabetes is seen as a manageable
disease nowadays, secondary complications of the current therapy
are considerable and lead to significant morbidity and mortality.
Using Nimvec™ AM510 we intend to restore the immune tolerance to
proinsulin and potentially cure the patients.
More information on www.amarnatherapeutics.com
Follow us on LinkedIn
https://www.linkedin.com/company/amarna-therapeutics-b.v.
For further inquiries please contact:
Amarna TherapeuticsHenk Streefkerk, CEOE-mail:
info@amarnatherapeutics.com
LifeSpring Life Sciences Communication, AmsterdamLéon
MelensTel: +31 6 538 16 427E-mail: lmelens@lifespring.nl
Aurelia Caparrós, New Chief Business Officer
Amarna Therapeutics, Leiden, The Netherlands